Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
- 1 February 1998
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 45 (2) , 107-114
- https://doi.org/10.1046/j.1365-2125.1998.00679.x
Abstract
Aims Chemical inhibitors of cytochrome P450 (CYP) are a useful tool in defining the role of individual CYPs involved in drug metabolism. The aim of the present study was to evaluate the selectivity and rank the order of potency of a range of isoform‐selective CYP inhibitors and to compare directly the effects of these inhibitors in human and rat hepatic microsomes. Methods Four chemical inhibitors of human cytochrome P450 isoforms, furafylline (CYP1A2), sulphaphenazole (CYP2C9), diethyldithiocarbamate (CYP2E1), and ketoconazole (CYP3A4) were screened for their inhibitory specificity towards CYP‐mediated reactions in both human and rat liver microsomal preparations. Phenacetin O‐deethylation, tolbutamide 4‐hydroxylation, chlorzoxazone 6‐hydroxylation and testosterone 6β‐hydroxylation were monitored for enzyme activity. Results Furafylline was a potent, selective inhibitor of phenacetin O‐deethylation (CYP1A2‐mediated) in human liver microsomes (IC50=0.48 μm ), but inhibited both phenacetin O‐deethylation and tolbutamide 4‐hydroxylation (CYP2C9‐mediated) at equimolar concentrations in rat liver microsomes (IC50=20.8 and 24.0 μm respectively). Sulphaphenazole demonstrated selective inhibition of tolbutamide hydroxylation in human liver microsomes but failed to inhibit this reaction in rat liver microsomes. DDC demonstrated a low level of selectivity as an inhibitory probe for chlorzoxazone 6‐hydroxylation (CYP2E1‐mediated). DDC also inhibited testosterone 6β‐hydroxylation (CYP3A‐mediated) in man and rat, and tolbutamide 4‐hydroxylase activity in rat. Ketoconazole was a very potent, selective inhibitor of CYP3A4 activity in human liver (IC50=0.04 μm ). Although inhibiting CYP3A in rat liver it also inhibited all other reactions at concentrations ≤5 μm. Conclusions It is evident that CYP inhibitors do not exhibit the same selectivity in human and rat liver microsomes. This is due to differential selectivity of the inhibitors and/or differences in the CYP isoform responsible for metabolism in the different species.Keywords
This publication has 40 references indexed in Scilit:
- Structural Basis of Selective Cytochrome P450 InhibitionAnnual Review of Pharmacology and Toxicology, 1995
- Review : Heterogeneity of cytochrome P450 and its toxicological significanceHuman & Experimental Toxicology, 1995
- P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancerXenobiotica, 1994
- Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazoneChemical Research in Toxicology, 1993
- In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their use in Drug DevelopmentDrug Metabolism Reviews, 1993
- Cytochromes P-450 in rats: structures, functions, properties and relevant human formsXenobiotica, 1992
- Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspectsChemical Research in Toxicology, 1991
- Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1Chemical Research in Toxicology, 1990
- Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitorsXenobiotica, 1990
- Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or .beta.-naphthoflavoneBiochemistry, 1982